



ASX Announcement

20 December 2018

Settlement of Kunna Canada Acquisition

Creso Pharma Limited (**CPH**) is pleased to announce that it has completed the acquisition of 100% of the shares in Kunna Canada Limited (incorporated under the laws of Ontario, Canada) (**Kunna**) (**Acquisition**).

By acquiring 100% of the issued capital in Kunna, CPH has also indirectly acquired 100% of Kunna's Colombian registered subsidiary, Kunna S.A.S. (**Kunna Colombia**), which in 2017 was granted (by the Colombian Ministry of Health) a licence to produce, manufacture, market and export cannabis derivatives and products, using extracts in Colombia. Additionally, in June 2018, Kunna Colombia was granted a licence to cultivate cannabis in Colombia.

Now that Kunna Colombia has received its cultivation licence, it intends to begin a full genetic and fertilisation research project and is progressing with its review of additional land for larger scale medicinal cannabis cultivation.

Completion of the Acquisition gives CPH a presence in the growing Colombian market for its innovative animal and human health nutraceutical products, and a foothold in the growing Latin American region, whilst also creating product commercialisation synergies.

The Acquisition will enable CPH to better integrate its supply chain, allowing it to produce its own medicinal cannabis as well as supply its existing planned products to the Colombian market.

The consideration for the Acquisition, being a total of 8,212,121 CPH shares and 1,212,120 performance shares, were today issued to the vendors of Kunna (as disclosed in CPH's Notice of Meeting announced on 11 September 2018).

The performance shares will convert into CPH shares on a one-for-one basis in the event Kunna Colombia is successful at the cultivation, extraction and sale of 10 kgs of cannabis extract (with a minimum of 6% CBD or 6% THC in flower), which must occur on commercial arm's length terms, from its operations within 18 months of today (i.e. no later than 20 June 2020).

As announced on 16 October 2018, all relevant shareholder approvals for the Acquisition, specifically the issues of the securities in accordance with ASX Listing Rule 7.1, were obtained at the General Meeting held 16 October 2018.



---END---

Corporate Queries:

EverBlu Capital
Level 39, Aurora Place
88 Phillip Street, Sydney, NSW
2000
E: info@everblucapital.com
P: +61 2 8249 0000



ASX Announcement

20 December 2018

Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Creso Pharma Limited (ASX:CPH, the “Company” or “Creso”) gives this notice pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (“Corporations Act”).

The Company advises that it has issued securities in the capital of the Company (“Securities”) per the attached Appendix 3B.

The Securities issued are part of a class of securities quoted on ASX and may be subject to a subsequent offer for sale. The Company advises that the Securities were issued without disclosure to investors under Part 6D.2 of the Act.

The Company, as at the date of this notice, has complied with:

- (a) the provisions of Chapter 2M of the Act as they apply to the Company; and
- (b) section 674 of the Corporations Act.

As at the date of this notice there is no information to be disclosed which is excluded information (as defined in section 708A(7) of the Corporations Act) that is reasonable for investors and their professional advisers to expect to find in a disclosure document.

---END---

About Creso Pharma

www.cresopharma.com

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp de-rived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Creso Pharma Limited

ABN

89 609 406 911

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|---|
| 1 | +Class of +securities issued or to be issued | <ol style="list-style-type: none">1. Fully Paid Ordinary Shares2. Performance Shares |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | <ol style="list-style-type: none">1. 8,212,1212. 1,212,120 |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | <ol style="list-style-type: none">1. Fully Paid Ordinary Shares2. Performance Shares. The Performance Shares will convert to Ordinary shares on a 1:1 basis in the event Kunna S.A.S. (an entity incorporated in Columbia) successfully cultivates, extracts and sells 10KG of cannabis extract from its operations within 18 months of settlement date. Full details of terms and conditions of these securities can be found in the Notice of Meeting dated 10 September 2018. |

Appendix 3B
New issue announcement

<p>4 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<ol style="list-style-type: none"> 1. Yes 2. No – the Performance Shares will rank equally upon satisfaction of the Performance Milestone and conversion into ordinary shares
<p>5 Issue price or consideration</p>	<ol style="list-style-type: none"> 1. Nil – deemed issue price of \$0.85 per Fully paid Ordinary Share 2. Nil – deemed Issue price of \$0.85 per Performance Share
<p>6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>Shares and Performance Shares have been issued as consideration for the acquisition of Kunna Canada Ltd as per the ASX announcements lodged 18 December 2017, and 23 July 2018. Issue of the Shares was approved by shareholders at a General Meeting held 16 October 2018 as per Notice of Meeting lodged with ASX on 11 September 2018.</p>
<p>6a Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p> <p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	<p>No</p>
<p>6b The date the security holder resolution under rule 7.1A was passed</p>	<p>N/A</p>

+ See chapter 19 for defined terms.

6c	Number of +securities issued without security holder approval under rule 7.1	N/A
6d	Number of +securities issued with security holder approval under rule 7.1A	N/A
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	<ol style="list-style-type: none"> 1. 8,212,121 Fully Paid Ordinary Shares 2. 1,212,120 Performance Shares (<i>subject to performance milestone</i>)
6f	Number of +securities issued under an exception in rule 7.2	N/A
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements	<p>7.1 – 13,202,838</p> <p>7.1A – N/A</p>

Appendix 3B

New issue announcement

7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

20 December 2018

8 Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
124,187,665	Ordinary fully paid shares (CPH) *
55,142,710	Listed CPHO Options (\$0.80; expiry 21/08/2020)
	*Includes this issue. This issue is subject to voluntary escrow as follows; 2,053,025 FPO Shares (escrowed to 19/03/19) 2,053,026 FPO Shares (escrowed to 19/06/19) 2,053,027 FPO Shares (escrowed to 19/09/19) 2,053,043 FPO Shares (escrowed to 19/12/19)

+ See chapter 19 for defined terms.

9 Number and
 +class of all
 +securities not
 quoted on ASX
 (including the
 +securities in
 section 2 if
 applicable)

600,000	Options Unlisted CPHOPT2 Options (\$0.40, 27/06/2020)*
2,886,250	Unlisted CPHOPT3 Options (\$0.20, 13/10/2020)*
2,250,000	Unlisted CPHOPT4 Options (\$0.20, 13/10/2019)
300,000	Unlisted CPHOPT5 Options (\$0.50, 23/01/2021)*
140,000	Unlisted CPHOPT10 Options (\$0.40, 27/07/2021)*
250,000	Unlisted CPHOPT11 Options (\$0.30, 27/07/2019)*
100,000	Unlisted CPHOPT12 Options (\$0.60, 27/07/2020)
250,000	Unlisted CPHOPT13 Options (\$0.80, 13/04/2019)
150,000	Unlisted CPHOPT14 Options (\$0.80, 13/07/2021)*
200,000	Unlisted CPHOPT16 Options (\$0.535, 27/07/2021)
200,000	Unlisted CPHOPT17 Options (\$0.80, 27/07/2022)
400,000	Unlisted CPHOPT18 Options (\$0.55, 21/08/2021)
200,000	Unlisted CPHOPT19 Options (\$0.80, 15/09/2022)
	Performance Shares
1,000,000	CPHPERSA Performance Shares*
303,027	CPHPERSB Performance Shares (escrowed to 19/03/19)*
303,027	CPHPERSC Performance Shares (escrowed to 19/06/19)*
303,027	CPHPERSD Performance Shares (escrowed to 19/09/19)*
303,039	CPHPERSE Performance Shares (escrowed to 19/12/19)*
	Performance Rights
5,000,000	CPHPERR4 Performance Rights*
800,000	CPHPERR6 Performance Rights (Tranche 1)*
800,000	CPHPERR7 Performance Rights (Tranche 2)*
1,250,000	CPHPERR8 Performance Rights (Tranche 3)*
1,250,000	CPHPERR9 Performance Rights (Tranche 4)*
100,000	CPHPERR13 Performance Rights (Tranche 8)*
150,000	CPHPERR14 Performance Rights (Tranche 9)*
100,000	CPHPERR15 Performance Rights (Tranche 16)*
100,000	CPHPERR16 Performance Rights (Tranche 17)*
2,000,000	CPHPERR19 Performance Rights (Tranche 12)*

Appendix 3B
New issue announcement

<p>9 Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)</p>	<p>50,000 132,000 132,000 132,000 200,000 100,000 300,000 300,000 300,000 100,000 150,000 150,000 500,000 400,000 400,000</p>	<p>Employee Performance Rights (Under Plan) CPHPERR21 Employee Performance Rights* CPHPERR22 Employee Performance Rights* CPHPERR23 Employee Performance Rights* CPHPERR24 Employee Performance Rights* CPHPERR27 Employee Performance Rights* CPHPERR28 Employee Performance Rights* CPHPERR29 Employee Performance Rights* CPHPERR30 Employee Performance Rights* CPHPERR31 Employee Performance Rights* CPHPERR32 Employee Performance Rights* CPHPERR33 Employee Performance Rights* CPHPERR34 Employee Performance Rights* CPHPERR35 Employee Performance Rights* CPHPERR36 Employee Performance Rights* CPHPERR37 Employee Performance Rights* <i>*Subject to performance milestones and/or vesting conditions.</i></p>
<p>10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)</p>	<p>N/A</p>	

Part 2 - Pro rata issue

<p>11 Is security holder approval required?</p>	<p>N/A</p>
<p>12 Is the issue renounceable or non-renounceable?</p>	<p>N/A</p>
<p>13 Ratio in which the +securities will be offered</p>	<p>N/A</p>
<p>14 +Class of +securities to which the offer relates</p>	<p>N/A</p>
<p>15 +Record date to determine entitlements</p>	<p>N/A</p>
<p>16 Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?</p>	<p>N/A</p>
<p>17 Policy for deciding entitlements in relation to fractions</p>	<p>N/A</p>

+ See chapter 19 for defined terms.

18	Names of countries in which the entity has security holders who will not be sent new offer documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	N/A
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the	N/A

Appendix 3B New issue announcement

- balance?
- 32 How do security holders dispose of their entitlements (except by sale through a broker)?
- 33 ⁺Issue date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of ⁺securities
(tick one)
- (a) ⁺Securities described in Part 1 (Shares only)
- (b) All other ⁺securities
Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

- 35 If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders
- 36 If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories
1 - 1,000
1,001 - 5,000
5,001 - 10,000
10,001 - 100,000
100,001 and over
- 37 A copy of any trust deed for the additional ⁺securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of +securities for which +quotation is sought	N/A					
39	+Class of +securities for which quotation is sought	N/A					
40	<p>Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	N/A					
41	<p>Reason for request for quotation now</p> <p>Example: In the case of restricted securities, end of restriction period</p> <p>(if issued upon conversion of another +security, clearly identify that other +security)</p>	N/A					
42	<p>Number and +class of all +securities quoted on ASX (including the +securities in clause 38)</p>	<table border="1"> <thead> <tr> <th data-bbox="788 1395 1090 1435">Number</th> <th data-bbox="1090 1395 1375 1435">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="788 1435 1090 1648">N/A</td> <td data-bbox="1090 1435 1375 1648"></td> </tr> </tbody> </table>	Number	+Class	N/A		
Number	+Class						
N/A							

Appendix 3B
New issue announcement

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



Date: 20 December 2018

Winton Willesee
Joint Company Secretary

== == == == ==

+ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital													
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated													
Insert number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	109,179,186												
<p>Add the following:</p> <ul style="list-style-type: none"> • Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 <table border="0" style="margin-left: 40px;"> <tr> <td style="text-align: right;">23/07/2018</td> <td style="text-align: right;">70,000 shares</td> </tr> <tr> <td style="text-align: right;">23/07/2018</td> <td style="text-align: right;">3,500,000 shares</td> </tr> </table> • Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval <table border="0" style="margin-left: 40px;"> <tr> <td style="text-align: right;">25/07/2018</td> <td style="text-align: right;">2,000,000 shares</td> </tr> <tr> <td style="text-align: right;">27/07/2018</td> <td style="text-align: right;">650,000 shares</td> </tr> </table> • Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period <table border="0" style="margin-left: 40px;"> <tr> <td style="text-align: right;">18/10/2018</td> <td style="text-align: right;">250,000 shares</td> </tr> <tr> <td style="text-align: right;">19/12/2018</td> <td style="text-align: right;">8,212,121 shares</td> </tr> </table> <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	23/07/2018	70,000 shares	23/07/2018	3,500,000 shares	25/07/2018	2,000,000 shares	27/07/2018	650,000 shares	18/10/2018	250,000 shares	19/12/2018	8,212,121 shares	
23/07/2018	70,000 shares												
23/07/2018	3,500,000 shares												
25/07/2018	2,000,000 shares												
27/07/2018	650,000 shares												
18/10/2018	250,000 shares												
19/12/2018	8,212,121 shares												
Subtract the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	Nil												
“A”	123,861,307												

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
Multiply “A” by 0.15	18,579,196

Appendix 3B
New issue announcement

Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used		
<p>Insert number of ⁺equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	21/12/2017	326,358 shares
	16/07/2018	150,000 options
	27/07/2018	400,000 options
	21/08/2018	200,000 options
	11/09/2018	400,000 options
	17/12/2018	3,900,000 options
“C”		5,376,358

Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	18,579,196
<p>Subtract “C”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	5,376,358
<p>Total [“A” x 0.15] – “C”</p>	<p>13,202,838</p> <p><i>this is the remaining placement capacity under rule 7.1</i></p>

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
<p>“A”</p> <p><i>Note: number must be same as shown in Step 1 of Part 1</i></p>	N/A
Step 2: Calculate 10% of “A”	
<p>“D”</p>	<p>0.10</p> <p><i>Note: this value cannot be changed</i></p>

+ See chapter 19 for defined terms.

Multiply "A" by 0.10	N/A
----------------------	-----

Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used

<p>Insert number of [†]equity securities issued or agreed to be issued in that 12 month period under rule 7.1A</p> <p>Notes:</p> <ul style="list-style-type: none"> • This applies to equity securities – not just ordinary securities • Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed • Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained • It may be useful to set out issues of securities on different dates as separate line items 	
"E"	

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

<p>"A" x 0.10</p> <p>Note: number must be same as shown in Step 2</p>	N/A
<p>Subtract "E"</p> <p>Note: number must be same as shown in Step 3</p>	
<p>Total ["A" x 0.10] – "E"</p>	<p>N/A</p> <p>Note: this is the remaining placement capacity under rule 7.1A</p>